News & Updates

Using biologic/small molecules*, systemic steroids, or other agents** to treat patients with inflammatory bowel disease (IBD) does not increase the rate of SARS-CoV-2 infection at 3 and 6 months post-immunization, according to a study presented at AIBD 2021.

In patients with inflammatory bowel disease (IBD), the likelihood of early treatment with vedolizumab is low, a finding that diverts from guideline recommendations, according to a real-world study presented at AIBD 2021.

A novel health tracker that is strapped around the wrist can detect changes in the physiology of individuals with inflammatory bowel disease (IBD) in real time, as shown in a study presented at the Advances in Inflammatory Bowel Diseases conference.

A remote, proactive, and telephone-based management of toxicities in outpatients during adjuvant or neoadjuvant chemotherapy for early-stage breast cancer does not lead to fewer visits to the emergency department (ED) or hospital admissions, a study has shown.

Patients with venous thromboembolism (VTE) who are new users of apixaban are less likely to experience recurrent VTE and bleeding than new users of rivaroxaban, a study has shown.

In a cohort of veterans with COVID-19, former smokers are at higher risk of 30-day mortality compared with current smokers and nonsmokers, as reported in a study.